Previous 10 | Next 10 |
A look at the top 10 most actives in the United States Crown Electrokinetics Corp. (CRKN) rose 16.4% to $0.199 on volume of 720,586,242 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 74.8% to $1.8 on volume of 682,362,254 shares Pineapple Energy Inc. (PEGY) rose 80.3% to $0.1...
2024-05-20 16:11:16 ET More on Dyne Therapeutics Dyne: H2 2024 Muscle Disease Data Could Boost Value Dyne Therapeutics: An Updated Analysis Dyne Therapeutics announces data from early stage trials of muscular dystrophy treatments Dyne Therapeutics appoints Jo...
2024-05-20 11:30:02 ET Guggenheim analyst issues BUY recommendation for DYN on May 20, 2024 09:22AM ET. The previous analyst recommendation was Buy. DYN was trading at $34.39 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst...
2024-05-20 11:30:02 ET H.C. Wainwright analyst issues BUY recommendation for DYN on May 20, 2024 09:31AM ET. The previous analyst recommendation was Buy. DYN was trading at $34.3919 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...
A look at the top 10 most actives in the United States Crown Electrokinetics Corp. (CRKN) rose 37.1% to $0.2344 on volume of 300,511,226 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 78.2% to $1.835 on volume of 218,102,513 shares Greenwave Technology Solutions Inc. (GWAV) r...
2024-05-20 09:58:45 ET More on PTC Therapeutics PTC Therapeutics: Multiple Regulatory Submissions Along With Data Cuts PTC Therapeutics, Inc. (PTCT) Q1 2024 Earnings Call Transcript PTC Therapeutics, Inc. (PTCT) Q4 2023 Earnings Call Transcript PTC Therapeuti...
2024-05-20 09:06:30 ET More on Dyne Therapeutics Dyne: H2 2024 Muscle Disease Data Could Boost Value Dyne Therapeutics: An Updated Analysis Dyne Therapeutics appoints John Cox CEO Dyne Therapeutics GAAP EPS of -$1.09 misses by $0.17 Seeking Alpha ...
- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose Dependent 27% Mean Splicing Correction Across All Patients in the 5.4 mg/kg Cohort at 3 Months - - DYNE-101 Showed Improvement in Myotonia, Muscle Strength, and Timed Function Tests and in DM1-ACTIV c and MDHI Patient Re...
WALTHAM, Mass., May 19, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced it now plans to report new ef...
2024-05-10 12:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
2024-07-21 03:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-24 16:00:09 ET Eun Yang from Jefferies issued a price target of $42.00 for DYN on 2024-06-24 12:31:00. The adjusted price target was set to $42.00. At the time of the announcement, DYN was trading at $35.94. The overall price target consensus is at $38.14 with hi...
WALTHAM, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced new preclinical data in a Po...